Pituitary Gland Disorders is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Pituitary Gland Disorders have a 90% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Pituitary Gland Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pituitary Gland Disorders overview

Pituitary gland disorders involve dysregulation of the pituitary, a crucial gland at the brain’s base responsible for hormone production. Tumors, inflammation, or dysfunction can disrupt hormonal balance, leading to overproduction or underproduction. Acromegaly, a common disorder, results from excess growth hormone, causing abnormal bone and tissue growth. Cushing’s disease, caused by elevated adrenocorticotropic hormone (ACTH), leads to cortisol overproduction, with symptoms like weight gain and high blood pressure. Conversely, hypopituitarism involves insufficient hormone production, causing fatigue, weight loss, and infertility. Tumors, head injuries, or genetics contribute to these disorders. Treatment varies, including surgery, medications, or hormone replacement therapy to restore balance and alleviate symptoms. Regular monitoring and follow-up care are crucial for effective pituitary gland disorder management.

For a complete picture of PTSR and LoA scores for drugs in Pituitary Gland Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.